The DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Abstract
Frontotemporal lobar degeneration (FTLD) describes a spectrum of clinically, pathologically and genetically heterogeneous neurodegenerative disorders of unknown aetiology. FTLD spectrum disorders collectively represent a leading cause of early-onset dementia, with most cases presenting between 45 and 64 years of age. FTLD is characterized by progressive changes in behaviour, executive dysfunction and/or language impairment and can be differentiated clinically into three frontotemporal dementia (FTD) syndromes as follows: (i) behavioural variant (bvFTD); (ii) semantic dementia (SD); and (iii) progressive nonfluent aphasia (PNFA). Additionally, there is a significant clinical, pathological and genetic overlap between FTD and motor neuron disease/amyotrophic lateral sclerosis (FTD-ALS) and the atypical parkinsonian syndromes, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). bvFTD is characterized by progressive behavioural impairment and a decline in executive function with frontal lobe-predominant atrophy, SD by a loss of object knowledge with prominent anomia and asymmetrical atrophy of the anterior temporal lobes and PNFA by expressive or motor speech deficits with predominantly left peri-sylvian atrophy. Recent advances in molecular biology and immunohistochemical staining techniques have further classified the FTLD spectrum disorders based upon the predominant neuropathological protein into three main categories: (i) microtubule-associated protein tau (FTLD-TAU); (ii) TAR DNA-binding protein-43 (FTLD-TDP); and (iii) fused in sarcoma protein (FTLD-FUS). Up to 40% of FTD patients report a family history of neurodegenerative illness, and one-third to one-half of familial cases of FTD follow an autosomal dominant inheritance pattern. Mutations in MAPT, PGRN, TARDBP, VCP and CHMP2B have been described, along with a recently identified C9ORF72 hexanucleotide repeat expansion. To date, there are no US FDA-approved treatments or disease-modifying therapies for FTD. Pharmacological strategies have focused on neurotransmitter replacement and modulation for the treatment of behavioural, motor and cognitive symptoms of FTD, and include selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, acetylcholinesterase inhibitors and glutamate NMDA receptor antagonists. At present, adequate management of FTD symptoms involves a combination of pharmacological therapy with behavioural, physical and environmental modification techniques.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FTLD is commonly identified in individuals between 45 and 65 years of age, yet its risk and occurrence increase with ageing. Research indicates an increased occurrence among older individuals, notably individuals aged 60 years and older.27”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [27]
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 9×
“[93,136] This chromosome 9 GGGGCC expansion accounts for more familial cases of ALS than any of the other formerly identified genetic causes of familial ALS, including SOD1, TARDBP, FUS, VCP and OPTN[136] and more familial cases of FTD thanMAPT and PGRN.[103] 7.”
BackgroundInfluentialImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690 · cited 1×
“A growing body of evidence suggests that the neuropeptide oxytocin enhances pro-social behaviour and emotion recognition both in healthy adults and in patients with autism.([207-209]) As recognition of negative facial expressions, such as fear and anger, is impaired in many patients with bvFTD,([210-212]) oxytocin may…”
BackgroundAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Research works printed but not linked: 9
- Pick, 1892, Prager Med Wochenschr, 17, 165
- Rascovsky, 2005, Neurology, 58, 1802
- Cardarelli, 2010, Am Fam Physician, 82, 1372
- Belfor, 2004, Neurology, 62, A237
- Feany, 1995, Am J Pathol, 146, 1388
- Rohrer, 2011, Brain, 134, 2565, 10.1093/brain/awr198 · DOI · Paper page
- He, 1999, Cancer Res, 59, 3222
- Ishii, 1998, J Nucl Med, 39, 1875
- Sperfeld, 1999, Ann Neurol, 46, 708, 10.1002/1531-8249(199911)46:5<708::aid-ana5>3.0.co;2-k · doi:10.1002/1531-8249(199911)46:5<708::aid-ana5>3.0.co;2-k
Cited by
Considering sex and gender in Alzheimer disease and other dementias
Podcasy, J. L., & Epperson, C. N. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/cepperson · Cited by 707
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD
Liu, Y., Pattamatta, A., Zu, T., Reid, T., Bardhi, O., Borchelt, D. R., Yachnis, A. T., & Ranum, L. P. W. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.005 · Cited by 374
Pathology and pathogenesis of vascular cognitive impairment—a critical update
Jellinger, K. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00017 · Cited by 353
“…et al., 2012), for Parkinson disease dementia (PDD) (Dubois et al., 2007; Emre et al., 2007), DLB (McKeith et al., 2005), frontotemporal lobe degeneration (FTLD) (Josephs et al., 2011; Seltman and Matthews, 2012), and other degenerative dementias (Karantzoulis and Galvin, 2011; Lopez et al., 2011).”
BackgroundLewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Metadata
- Authors
- Seltman, R. E., & Matthews, B. R.
- Affiliations
- Indiana University School of Medicine (US)
- Corresponding author
- Matthews, Brandy R.
- Venue
- CNS Drugs
- Published
- 2012-10
- Volume
- 26
- Issue
- 10
- Pages
- 841-870
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W1605023419
- Cited by
- 132
- References
- 223
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 3 · 2022: 8 · 2021: 10 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 8 · 2016: 20 · 2015: 17 · 2014: 13 · 2013: 12 · 2012: 1
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG010133)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- frontotemporal lobar degeneration, frontotemporal dementia, behavioral variant frontotemporal dementia, semantic dementia, progressive nonfluent aphasia, progressive supranuclear palsy, corticobasal syndrome, tauopathy, TDP-43, FUS, genetic mutations, C9orf72 repeat expansion, early-onset dementia, executive dysfunction, language impairment, pharmacotherapy, acetylcholinesterase inhibitors, NMDA receptor antagonists, atypical antipsychotics, selective serotonin reuptake inhibitors
- MeSH terms
- Humans, Neurodegenerative Diseases, Frontotemporal Lobar Degeneration, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management. https://app.cochat.ai/papers/10.2165/11640070-000000000-00000
- The paper
- Seltman, R. E., & Matthews, B. R. (2012). Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management. CNS Drugs. https://doi.org/10.2165/11640070-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.